The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 1, 2007, Pages 1-4

  Goldstein, F ^a  

^a SAINT JOSEPH HOSPITAL   (France)

Author keywords

Antimicrobials; Borderline activity; Staphylococci

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTOBIPROLE; CHLORAMPHENICOL ACETYLTRANSFERASE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; FUSIDIC ACID; KANAMYCIN; LINCOMYCIN; LINEZOLID; MOXIFLOXACIN; PENICILLINASE; POLYPEPTIDE ANTIBIOTIC AGENT; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TETRACYCLINE; TRIMETHOPRIM; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; CROSS RESISTANCE; CULTURE MEDIUM; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG TISSUE LEVEL; DRUG TREATMENT FAILURE; EDITORIAL; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; NONHUMAN; PHARMACODYNAMICS; REFERENCE VALUE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; STAPHYLOCOCCUS AUREUS; VIRULENCE;

EID: 33845872274     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl429     Document Type: Editorial

References (37)

1. Baquero F. Low-level antibacterial resistance: A gateway to clinical resistance. Drug Resist Updat 2001; 4: 93-105.
2. Kahlmeter G, Brown DF, Goldstein FW et al. A European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 2003; 52: 145-8.
3. Report of the Comité de l'Antibiogramme de la Société Française de Microbiologie. Clin Microbiol Infect 1996; 2 Suppl 1: 1-49.
4. Leclercq R. Macrolides-lincosamides-streptogramines. Antibiogramme des principaux groupes bactériens. In: Courvalin P, Leclercq R, Bingen E, eds. Antibiogramme. Paris: ESKA Editions, 2006; 299-324.
5. Bismuth R. Aminosides et bactéries à Gram positif. In: Courvalin P, Leclercq R, Bingen E, eds. Antibiogramme. Paris: ESKA Editions, 2006; 205-26.
6. Acar JF, Goldstein FW, Lagrange P. Human infections caused by thiamine- or menadione-requiring Staphylococcus aureus. J Clin Microbiol 1978; 8: 142-7.
7. Kitzis MD, Goldstein FW. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 2006; 12: 92-5.
8. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: A new model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147-55.
9. Shanson DC. Clinical relevance of resistance to fusidic acid in Staphylococcus aureus. J Antimicrob Chemother 1990; 25 Suppl B: 15-21.
10. Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci 2005; 330: 102-4.
11. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-8.
12. Wilson P, Andrews JA, Charlesworth R et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003; 51: 186-8.
13. Hayden MK, Rezai K, Hayes RA et al. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43: 5285-7.
14. Goldstein FW, Kitzis MD. Vancomycin-resistant Staphylococcus aureus: No apocalypse now. Clin Microbiol Infect 2003; 9: 761-5.
15. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44: 655-6.
16. Asseray N, Caillon J, Roux N et al. Different aminoglycoside-resistant phenotypes in a rabbit Staphylococcus aureus endocarditis infection model. Antimicrob Agents Chemother 2002; 46: 1591-3.
17. Zarrouk V, Bozdogan B, Leclercq R et al. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics. Antimicrob Agents Chemother 2001; 45: 1244-8.
18. Renzoni A, François P, Li D et al. Modulation of fibronectin adhesins and other virulence factors in a teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48: 2958-65.
19. Vaudaux P, François P, Berger-Bachi B et al. In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus. J Antimicrob Chemother 2001; 47: 163-70.
20. B operon in Staphylococcus aureus. J Bacteriol 2005; 187: 8006-19.
21. Sakoulas G, Eliopoulos GM, Moellering RC Jr et al. Staphylococcus aureus accessory gene regulator (agr) group II: Is there a relationship to the development of intermediate-level glycopeptide-resistance? J Infect Dis 2003; 187: 929-38.
22. B is involved in regulation of biofilm expression in a Staphylococcus aureus mucosal isolate. J Bacteriol 2000; 182: 6824-6.
23. Fitzpatrick F, Humphreys H, O'Gara JP. The genetics of staphylococcal biofilm formation - will a greater understanding of pathogenesis lead to better management of device-related infection? Clin Microbiol Infect 2005; 11: 967-73.
24. Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant mircroorganisms. Clin Microbiol Rev 2002; 15: 167-93.
25. Mathur T, Singhal S, Khan S et al. Adverse effect of staphylococci slime on in vitro activity of glycopeptides. J Infect Dis 2005; 58: 353-7.
26. Cui L, Tominaga E, Neoh HM et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-82.
27. Sakoulas G, Alder J, Thauvin-Eliopoulos C et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50: 1581-5.
28. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 2004; 64: 159-204.
29. Noguchi N, Okada H, Narui K et al. Comparison of the nucleotide sequence and expression of norA genes and microbial susceptibility in 21 strains of Staphylococcus aureus. Microb Drug Resist 2004; 10: 197-203.
30. Soria C. Resistance de Staphylococcus aureus aux antiseptiques. Thesis. Faculté de Pharmacie, Chatenay-Malabry, Paris, France, 2004.
31. Dong Y, Zhao X, Domagala J et al. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 1756-8.
32. Besier S, Ludwig A, Brade V et al. Compensatory adaptation to the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 1426-31.
33. Moisan H, Brouillette E, Jacob CL et al. Transcription of virulence factors in Staphylococcus aureus small-colony variants isolated from cystic fibrosis patients is influenced by SigB. J Bacteriol 2006; 188: 64-76.
34. Yu J, Wu J, Francis KP et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother 2005; 55: 528-34.
35. Von Eiff C, Proctor RA, Peters G. Small colony variants of staphylococci: A link to persistent infections. Berl Munch Tierarztl Wochenschr 2000; 113: 321-5.
36. Vaudaux P, François P, Bisognano C et al. Increased expression of clumping factor and fibronectin-binding proteins by hemB mutants of Staphylococcus aureus expressing small colony variant phenotypes. Infect Immun 2002; 70: 5428-37.
37. Von Eiff C, Friedrich AW, Becker K et al. Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes. Antimicrob Agents Chemother 2005; 49: 4372-4.